Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

he requirements and plans for regulatory filings and approvals for clofarabine in additional indications. These risks and uncertainties include, among others, the timing and results of clinical studies for clofarabine; the timing of discussions with the EMEA and FDA regarding clinical study results and approval of clofarabine in additional indications; the timing and content of decisions by the EMEA and FDA related to clinical trials and approval of clofarabine in additional indications; the actual efficacy and safety of clofarabine for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Evoltra(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.

Media Contact: Investor Contact:

Maria Cantor Patrick Flanigan

(617) 768-6690 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... OSAKA, Japan , April 16, 2015 ... of Kyoto University and Takeda Pharmaceutical Company Limited ... to develop clinical applications of induced pluripotent stem ... mellitus, neurological disorders and cancer immunotherapy. The "Takeda-CiRA ... designed to expedite multiple research projects for drug ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased to ... for the 2015 BIO International Convention. Hosted by the ... will take place June 15-18 at the Pennsylvania Convention ... contest, industry leaders will be voting for companies they ... community voting period began on April 14, 2015 and ...
(Date:4/16/2015)... N.C. (PRWEB) April 16, 2015 ... Carolina at Charlotte (UNC Charlotte) spin-out company, announced ... L. Cooper, Ph.D., M.D., as Chief Operating Officer ... years of experience in developing clinical diagnostic and ... and infectious disease. , Cooper’s extensive career transcends ...
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... Millstone Medical Outsourcing,announced today that the company ... accommodate growing business with new and existing customers ... new facility, located at,580 Commerce Drive, includes 27,000 ... advanced inspection services, ultrasonic cleaning,and sterile and non-sterile ...
... six-year battle with heart disease that included numerous medications, trips to the ... himself in the Intensive Care Unit at an Ohio hospital. Both sides ... a transplant. , ... TUCSON, Ariz. (Business Wire EON) October 8, ...
... from Top Industry Analyst -, EVANSTON, Ill., ... across industries manage a wide range of sales ... a global management,consulting firm specializing in sales and ... new Javelin(TM) Software Suite provides a unified platform ...
Cached Biology Technology:Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity 2 "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest™ temporary Total Artificial Heart 2Newly Integrated Software Suite From ZS Associates Offers Comprehensive Set of Sales Performance Management Software Solutions 2Newly Integrated Software Suite From ZS Associates Offers Comprehensive Set of Sales Performance Management Software Solutions 3
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... ever met a cat that doesn't go crazy over catnip? ... world don't respond to it at all, according to the ... Chemical & Engineering News, the weekly newsmagazine published by the ... sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian at ...
... responsible for controlling a first key step in the creation ... journal Nature tomorrow (Thursday 27 October 2005). , The gene, ... once a sperm enters an egg, giving it a crucial ... , The absence or mutation of this gene in the ...
... China have an increased risk of schizophrenia, consistent with ... and schizophrenia, according to a study in the August ... and human rights. , Schizophrenia is a common form ... and delusions, as well a as deterioration of social ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists unpick genetics of first 15 minutes of life 2Prenatal exposure to famine increases risk of schizophrenia 2
... 2-Methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidine-4-one White solid. PROTECT FROM ... and water soluble pyrimidinone compound that acts ... inhibitor of PARP (IC 50 = ... and rmPARP2, respectively) with little activity against ...
... on the ease of use and flexibility of the ... introduces the BDTM LSR II. The BD LSR ... in a benchtop analyzer. Free up your high-performance ... UV laser to the BD LSR II. The BD ...
... The DNA Engine Opticon 2 real-time ... of LEDs for fluorescence excitation (470-505 nm) ... (523-543 nm, 540-700 nm). The Opticon 2 ... thermal cycler, which includes a thermal gradient ...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: